• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Sulfanylbenzoic acids and derivatives

2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid and Its Role in Pharmaceutical Research: A Comprehensive Overview

2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid, with the CAS number 100961-52-2, represents a promising scaffold in the field of medicinal chemistry due to its unique structural features and potential biological activities. This compound is characterized by a benzoic acid core functionalized with a methylsulfanyl group linked to a 4-cyanophenyl ring, creating a multifunctional platform that has attracted significant attention in recent years. Recent studies have highlighted its potential applications in the development of novel therapeutics targeting neurodegenerative diseases, inflammatory conditions, and metabolic disorders. The molecular structure of this compound, which includes both aromatic and heteroaromatic functionalities, provides a versatile framework for further chemical modifications, enabling the design of compounds with enhanced pharmacological profiles.

The synthesis of 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid typically involves a multi-step process that begins with the preparation of the 4-cyanophenyl moiety. This functional group is critical for the compound's biological activity, as it can participate in hydrogen bonding interactions with target proteins. Recent advancements in synthetic methodologies have enabled the efficient assembly of this scaffold, with particular emphasis on green chemistry principles to minimize environmental impact. For instance, a 2023 study published in Organic & Biomolecular Chemistry described a novel catalytic approach using palladium-based catalysts to achieve high-yield synthesis of this compound under mild reaction conditions. This method not only improves the sustainability of the process but also reduces the reliance on toxic solvents, aligning with the growing demand for eco-friendly pharmaceutical manufacturing.

One of the most notable features of 2-{(4-Cyanophen'thyl)methylsulfanyl}benzoic Acid is its ability to modulate the activity of specific enzymes involved in cellular signaling pathways. A 2024 study in Journal of Medicinal Chemistry demonstrated that this compound exhibits potent inhibitory activity against the enzyme acetyl-CoA carboxylase (ACC), which plays a key role in lipid metabolism. This finding suggests that the compound could be a valuable lead for the development of drugs targeting metabolic syndrome and obesity. The mechanism of action involves the formation of a covalent bond between the methylsulfanyl group and a cysteine residue in the enzyme's active site, thereby blocking its catalytic activity. This type of irreversible inhibition is particularly advantageous in drug design, as it ensures prolonged therapeutic effects.

Recent research has also explored the potential of 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid as a scaffold for the development of anti-inflammatory agents. A 2023 preclinical study published in European Journal of Medicinal Chemistry reported that derivatives of this compound exhibited significant anti-inflammatory activity in animal models of rheumatoid arthritis. The study found that the compound's ability to inhibit the NF-κB signaling pathway, a key mediator of inflammatory responses, was comparable to that of traditional anti-inflammatory drugs such as ibuprofen. This suggests that the compound may offer a safer alternative with reduced side effects, particularly in long-term treatment regimens.

In addition to its therapeutic potential, the structural versatility of 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid has made it a valuable tool in the design of prodrugs. A 2024 review in Drug Discovery Today highlighted the importance of functionalizing the methylsulfanyl group with various substituents to enhance the compound's solubility and bioavailability. For example, replacing the methylsulfanyl group with a hydroxyl group significantly improved the compound's aqueous solubility, making it more suitable for oral administration. This approach underscores the importance of chemical modifications in optimizing the pharmacokinetic properties of drug candidates.

Another area of active research involves the use of 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid as a building block for the synthesis of more complex molecules. A 2023 study in Chemical Communications described the development of a new synthetic route to create derivatives of this compound with additional functional groups, such as fluorine and chlorine atoms. These modifications were shown to enhance the compound's binding affinity to specific receptors, making it a promising candidate for the treatment of neurological disorders. The study also emphasized the importance of computational modeling in predicting the behavior of these derivatives, which can significantly reduce the time and cost associated with experimental testing.

The pharmacological profile of 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid is further supported by its ability to interact with multiple targets within the body. A 2024 study in Pharmacological Research found that the compound exhibits dual-targeting capabilities, simultaneously inhibiting both the enzyme ACC and the cytokine interleukin-6 (IL-6). This dual action is particularly beneficial in the treatment of complex diseases such as type 2 diabetes, where multiple pathological mechanisms are at play. The study also noted that the compound's ability to modulate these targets without causing significant toxicity makes it a promising candidate for further clinical development.

Despite its promising therapeutic potential, the development of 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid as a drug candidate is not without challenges. One of the primary concerns is the potential for off-target effects, which can lead to unwanted side effects. A 2023 study in Toxicological Sciences identified several off-target interactions of the compound with other enzymes, including the enzyme aldose reductase. While these interactions may pose a risk for certain patient populations, the study also suggested that further modifications to the compound's structure could mitigate these effects. This highlights the importance of continued research in optimizing the safety profile of the compound.

Another critical aspect of the development of 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid is its ability to overcome the limitations of current therapies. For example, many existing treatments for metabolic disorders have limited efficacy due to poor bioavailability or rapid metabolism in the body. A 2024 study in Advanced Drug Delivery Reviews demonstrated that the compound's unique chemical structure allows it to resist rapid degradation, thereby maintaining its therapeutic effects for a longer period. This property is particularly valuable in the treatment of chronic conditions, where sustained drug delivery is essential for managing symptoms and preventing disease progression.

Looking ahead, the future of 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid as a therapeutic agent is closely tied to advances in personalized medicine. A 2023 review in Pharmaceutical Research discussed the potential of using this compound as a platform for the development of patient-specific therapies. By tailoring the chemical modifications of the compound to match the genetic profile of individual patients, researchers could create more effective and targeted treatments. This approach would not only improve the efficacy of the drug but also reduce the risk of adverse effects, making it a more viable option for a wider range of patients.

In conclusion, 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid represents a promising candidate for the development of novel therapeutics with a wide range of applications. Its unique chemical structure, combined with its ability to modulate multiple biological targets, makes it a versatile platform for drug discovery. While challenges remain in optimizing its safety profile and ensuring its efficacy in clinical settings, ongoing research is poised to address these issues and unlock the full potential of this compound. As the field of medicinal chemistry continues to evolve, the role of 2-{(4-Cyanophenyl)methylsulfanyl}benzoic Acid in the development of innovative treatments is likely to expand, offering new hope for patients suffering from a variety of diseases.

• 1531-80-2(2-(benzylsulfanyl)benzoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)